{"id":742,"date":"2026-04-08T13:58:22","date_gmt":"2026-04-08T09:58:22","guid":{"rendered":"https:\/\/healthfinder.ae\/blog\/?p=742"},"modified":"2026-04-08T15:35:47","modified_gmt":"2026-04-08T11:35:47","slug":"alt-ast-ratio-alcoholic-nafld-uae","status":"publish","type":"post","link":"https:\/\/healthfinder.ae\/blog\/alt-ast-ratio-alcoholic-nafld-uae\/","title":{"rendered":"ALT\/AST Ratio Explained (2025): ALD vs NAFLD in UAE"},"content":{"rendered":"

In 2025, the ALT\/AST ratio has become a critical liver diagnostic marker in UAE healthcare, especially for distinguishing between alcoholic liver disease and non-alcoholic fatty liver disease (NAFLD). This ratio compares the levels of two enzymes\u2014alanine aminotransferase (ALT), which is more specific to liver tissue, and aspartate aminotransferase (AST), which is found in both liver and muscle.<\/span><\/p>\n

To understand how these enzymes are measured and interpreted in liver function tests, read our detailed guide on SGOT and SGPT tests in UAE<\/a><\/strong><\/span>.<\/span><\/p>\n

A ratio greater than 2:1 typically indicates alcohol-related liver damage such as alcoholic steatohepatitis, while a ratio below 1 usually suggests metabolic liver conditions like NAFLD or its more severe form, non-alcoholic steatohepatitis (NASH). Physicians across Dubai Health Authority (DHA) and SEHA facilities routinely use the ALT\/AST ratio during preclinical screenings and liver consultations to guide diagnostic and referral decisions.<\/span><\/p>\n

In a region facing rising metabolic syndrome and lifestyle-driven liver disease, early interpretation of ALT and AST levels helps clinicians determine whether to refer patients for alcohol-use evaluation, fibrosis staging via FibroScan, or metabolic risk profiling and lifestyle interventions\u2014making this ratio a frontline tool in liver health management.<\/span><\/p>\n

According to a 2023 study published in the Journal of Hepatology, NAFLD affects approximately 32% of adults in the Middle East, with UAE prevalence expected to rise significantly. Projections by GlobalData Healthcare estimate that by 2030, the number of NAFLD cases in the UAE could exceed 372,000, reinforcing the importance of early, enzyme-based liver disease differentiation.<\/span><\/p>\n

What Is the ALT\/AST (De Ritis) Ratio?<\/strong><\/span><\/h2>\n

The ALT\/AST ratio\u2014also known as the De Ritis ratio\u2014is a valuable clinical marker used to interpret liver enzyme profiles. It compares alanine aminotransferase (ALT) to aspartate aminotransferase (AST):<\/span><\/p>\n

ALT \u00f7 AST<\/strong><\/span><\/p>\n

ALT is primarily localized in the cytosol of hepatocytes, making it highly specific to liver cell injury. By contrast, AST is distributed across both the cytosol and mitochondria and is present in various tissues, including skeletal muscle, cardiac muscle, and the brain\u2014which makes it less liver-specific and more reflective of multisystemic damage.<\/span><\/p>\n

How is the ALT\/AST ratio used in UAE healthcare?<\/strong><\/span><\/h3>\n

\"How<\/p>\n

In 2025 UAE clinical settings, particularly within DHA and SEHA facilities, the ALT\/AST ratio is routinely assessed as part of liver function testing. These enzymes are also covered in depth in our SGOT\/SGPT enzyme analysis<\/a><\/strong><\/span> guide, which outlines typical reference ranges and clinical relevance. This ratio provides essential diagnostic insights into the underlying cause of enzyme elevation:<\/span><\/p>\n

ALT\/AST ratio <1 is often observed in alcoholic liver disease (ALD), particularly in alcoholic steatohepatitis (ASH), due to mitochondrial AST release.<\/span><\/p>\n

Given the growing burden of both metabolic syndrome and alcohol-related liver disorders in the UAE, the De Ritis ratio plays a central role in differentiating between these conditions. It informs downstream diagnostic strategies such as FibroScan\u00ae for non-invasive fibrosis staging and guides referrals to hepatology or endocrinology specialists based on the suspected cause.<\/span><\/p>\n

By integrating enzyme ratios into routine screenings, UAE clinicians can better triage patients, ensure timely interventions, and deliver more personalized liver care\u2014whether in public hospitals or private specialty centers.<\/span><\/p>\n

Understanding the ALT\/AST Ratio: Clinical Meaning & Thresholds<\/strong><\/span><\/h2>\n

\"Understanding<\/p>\n

The ALT\/AST ratio (De Ritis ratio) is a clinically validated tool for identifying the source and severity of liver injury. It compares alanine aminotransferase (ALT) to aspartate aminotransferase (AST) and guides differential diagnosis between alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and viral hepatitis.<\/span><\/p>\n

In UAE healthcare systems\u2014especially within DHA and SEHA workflows\u2014the ALT\/AST ratio supports early triage, hepatology referral, and further diagnostic evaluation.<\/span><\/p>\n

ALT\/AST Ratio Thresholds and Clinical Interpretation<\/strong><\/span><\/p>\n

The table below summarizes how specific ALT\/AST ratio thresholds correlate with underlying liver pathology, helping clinicians differentiate between alcohol-induced and metabolic liver injuries.<\/span><\/p>\n\n\n\n\n\n\n\n
ALT\/AST Ratio<\/span><\/strong><\/span><\/th>\nInterpretation<\/span><\/strong><\/span><\/th>\nCommon Causes<\/span><\/strong><\/span><\/th>\n<\/tr>\n<\/thead>\n
< 1.0<\/span><\/td>\nAST > ALT \u2192 Mitochondrial-dominant injury<\/span><\/td>\nAlcoholic hepatitis, cirrhosis<\/span><\/td>\n<\/tr>\n
\u2248 1.0<\/span><\/td>\nALT \u2248 AST \u2192 Non-specific elevation<\/span><\/td>\nEarly liver injury, mild hepatopathy<\/span><\/td>\n<\/tr>\n
> 1.2<\/span><\/td>\nALT > AST \u2192 Cytosolic-dominant leakage<\/span><\/td>\nNAFLD, NASH, viral hepatitis<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Clinical Notes:<\/strong><\/span><\/p>\n